GUILDFORD, England, January 29, 2019 /PRNewswire/ -- HOX Therapeutics, the private biotechnology company developing first-in-class, highly targeted cancer therapies based on HOX genes, announces the appointment of Dr Stephen Shuttleworth as Non-Executive Director. Stephen is currently CSO ...
from PR Newswire: https://prn.to/2Unrkc0
No comments:
Post a Comment